Literature DB >> 6683587

Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells.

K J Scanlon, R L Safirstein, H Thies, R B Gross, S Waxman, J B Guttenplan.   

Abstract

The uptake of cis-diamminedichloroplatinum(II) (cisplatin) has been studied in the L1210 murine lymphoid leukemia cell line. Labeled cisplatin and its aquated derivatives were resolved by high-performance liquid chromatography on a strong cationic exchange column. After 10 min of incubation of cisplatin with the cells, the major portion of the non-protein-bound platinum was in the form of cisplatin. However, a portion of this platinum was converted with time to a derivative which coeluted with the monoaquo derivative of cisplatin. With the appearance of this derivative, there was a concomitant inhibition of sodium-dependent amino acid transport as measured by the uptake of aminoisobutyric acid and methionine. Furthermore, the exposure of L1210 cells to a preparation of predominantly aquated product(s) of cisplatin inhibited amino acid uptake following a brief (2-min) incubation, whereas measurable inhibition of amino acid uptake by cisplatin required a longer preincubation period. This inhibition of aminoisobutyric acid and methionine was dependent on the concentration of platinum. Aminoisobutyric acid and methionine were shown to be concentrated in L1210 cells in the presence of sodium ions, and competition experiments suggest similar uptake systems. Since L1210 cells are methionine-auxotrophic leukemic cells, inhibition of essential amino acid transport by cisplatin may be a mechanism of cytotoxic action.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683587

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.

Authors:  K J Scanlon; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.

Authors:  Y J Lidor; K C O'Briant; F J Xu; T C Hamilton; R F Ozols; R C Bast
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

3.  Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line.

Authors:  H Schaider; U Haberkorn; M R Berger; F Oberdorfer; I Morr; G van Kaick
Journal:  Eur J Nucl Med       Date:  1996-01

4.  Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.

Authors:  P J O'Dwyer; M J Cornfeld; R Peter; R L Comis
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

Authors:  A de Graeff; R J Slebos; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  The role of methionine in methotrexate-sensitive and methotrexate-resistant mouse leukemia L1210 cells.

Authors:  K J Scanlon; M Kashani-Sabet; A R Cashmore; M Pallai; B A Moroson; M Saketos
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial.

Authors:  Fumitake Hata; Kazuaki Sasaki; Koichi Hirata; Susumu Yamamitsu; Tetsuhiko Shirasaka
Journal:  Surg Today       Date:  2008-07-09       Impact factor: 2.549

8.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

Authors:  K J Scanlon; E M Newman; Y Lu; D G Priest
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.

Authors:  P A Steerenberg; C P Vendrik; W H de Jong; G de Groot; A M Fichtinger-Schepman; A P Scheefhals; J H Schornagel
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C.

Authors:  J Hofmann; F Ueberall; L Posch; K Maly; D B Herrmann; H Grunicke
Journal:  Lipids       Date:  1989-04       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.